Literature DB >> 31135395

Treatable traits in chronic rhinosinusitis with nasal polyps.

Enrico Heffler1,2, Luca Malvezzi3, Francesca Pirola3, Natalia Zięba4, Giovanni Paoletti1,2, Giuseppe Mercante2,3, Giuseppe Spriano2,3, Giorgio Walter Canonica1,2.   

Abstract

PURPOSE OF REVIEW: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a complex inflammatory sinonasal disease that deserves a multidisciplinary precision medicine approach. In a precision medicine model, a more pragmatic approach taking in consideration disease features that are potentially treatable should be considered. RECENT
FINDINGS: Several treatable traits in CRSwNP can be identified: from disease-related ones, to extra-ENT features, to behavioral and environmental factors. This review article summarizes primarily the recent findings of CRSwNP-related treatable traits and how they can be modified by given treatments.
SUMMARY: The advent of biological agents acting directly to the endotype underlying CRSwNP pushes the scientific community to integrate clinical, surgical and immunological evaluations for each single patient; this naturally leads to the identification of specific treatable traits that can serve as possible outcomes for any single biological.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31135395     DOI: 10.1097/ACI.0000000000000544

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  4 in total

Review 1.  Personalized Management of Patients with Chronic Rhinosinusitis with Nasal Polyps in Clinical Practice: A Multidisciplinary Consensus Statement.

Authors:  Eugenio De Corso; Maria Beatrice Bilò; Andrea Matucci; Veronica Seccia; Fulvio Braido; Matteo Gelardi; Enrico Heffler; Manuela Latorre; Luca Malvezzi; Girolamo Pelaia; Gianenrico Senna; Paolo Castelnuovo; Giorgio Walter Canonica
Journal:  J Pers Med       Date:  2022-05-23

2.  Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis.

Authors:  Enrico Heffler; Fabiana Saccheri; Marta Bartezaghi; Giorgio Walter Canonica
Journal:  Clin Transl Allergy       Date:  2020-06-26       Impact factor: 5.871

Review 3.  Interleukin-5 in the Pathophysiology of Severe Asthma.

Authors:  Corrado Pelaia; Giovanni Paoletti; Francesca Puggioni; Francesca Racca; Girolamo Pelaia; Giorgio Walter Canonica; Enrico Heffler
Journal:  Front Physiol       Date:  2019-12-17       Impact factor: 4.566

4.  Treatable Traits in Chronic Respiratory Disease: A Comprehensive Review.

Authors:  Yong Qin Lee; Asvin Selvakumar; Kay Choong See
Journal:  Cells       Date:  2021-11-22       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.